Skip to main content Back to Top
Advertisement

10/18/2019

Mycophenolate Mofetil Capsules and Tablets

Products Affected - Description

    • Mycophenolate Mofetil oral capsule, Accord, 250 mg, bottle, 100 count, NDC 16729-0094-01
    • Mycophenolate Mofetil oral capsule, Accord, 250 mg, bottle, 500 count, NDC 16729-0094-16
    • Mycophenolate Mofetil oral tablet, Accord, 500 mg, bottle, 100 count, NDC 16729-0019-01
    • Mycophenolate Mofetil oral tablet, Accord, 500 mg, bottle, 500 count, NDC 16729-0019-16
    • Mycophenolate Mofetil oral capsule, Ascend, 250 mg, bottle, 100 count, NDC 67877-0266-01
    • Mycophenolate Mofetil oral capsule, Ascend, 250 mg, bottle, 500 count, NDC 67877-0266-05
    • Mycophenolate Mofetil oral tablet, Ascend, 500 mg, bottle, 100 count, NDC 67877-0225-01
    • Mycophenolate Mofetil oral tablet, Ascend, 500 mg, bottle, 500 count, NDC 67877-0225-05
    • Mycophenolate Mofetil oral capsule, Hikma, 250 mg, bottle, 100 count, NDC 00054-0163-25
    • Mycophenolate Mofetil oral capsule, Hikma, 250 mg, bottle, 500 count, NDC 00054-0163-29
    • Mycophenolate Mofetil oral tablet, Hikma, 500 mg, bottle, 100 count, NDC 00054-0166-25
    • Mycophenolate Mofetil oral tablet, Hikma, 500 mg, bottle, 500 count, NDC 00054-0166-29
    • Mycophenolate Mofetil oral capsule, Mylan, 250 mg, bottle, 100 count, NDC 00378-2250-01
    • Mycophenolate Mofetil oral capsule, Mylan, 250 mg, bottle, 500 count, NDC 00378-2250-05
    • Mycophenolate Mofetil oral capsule, Mylan, 250 mg, unit-dose blister pack, 100 count, NDC 51079-0721-20
    • Mycophenolate Mofetil oral tablet, Mylan, 500 mg, bottle, 100 count, NDC 00378-4472-01
    • Mycophenolate Mofetil oral tablet, Mylan, 500 mg, bottle, 500 count, NDC 00378-4472-05
    • Mycophenolate Mofetil oral tablet, Mylan, 500 mg, unit-dose blister pack, 100 count, NDC 51079-0379-20
    • Mycophenolate Mofetil oral capsule, Sandoz, 250 mg, bottle, 1440 count, NDC 00781-2067-89

Reason for the Shortage

    • Accord did not provide a reason for the shortage.
    • Ascend did not provide a reason for the shortage.
    • Hikma did not provide a reason for the shortage.
    • Mylan did not provide a reason for the shortage.
    • Genentech has Cellcept available.
    • Sandoz did not provide a reason for the shortage.

Available Products

    • CellCept oral capsule, Genentech, 250 mg, bottle, 100 count, NDC 00004-0259-01
    • CellCept oral capsule, Genentech, 250 mg, bottle, 500 count, NDC 00004-0259-43
    • CellCept oral tablet, Genentech, 500 mg, bottle, 100 count, NDC 00004-0260-01
    • CellCept oral tablet, Genentech, bottle, 500 count, NDC 00004-0260-43
    • Mycophenolate Mofetil oral capsule, Sandoz, 250 mg, bottle, 100 count, NDC 00781-2067-01
    • Mycophenolate Mofetil oral capsule, Sandoz, 250 mg, bottle, 500 count, NDC 00781-2067-05
    • Mycophenolate Mofetil oral tablet, Sandoz, 500 mg, bottle, 100 count, NDC 00781-5175-01
    • Mycophenolate Mofetil oral tablet, Sandoz, 500 mg, bottle, 500 count, NDC 00781-5175-05

Estimated Resupply Dates

    • Accord has all mycophenolate mofetil presentations on allocation.
    • Ascend has all mycophenolate mofetil presentations on intermittent back order and the company is releasing product as it becomes available.
    • Hikma has mycophenolate mofetil 250 mg capsules in 100 count and 500 count and 500 mg tablets in 100 count and 500 count on allocation.
    • Mylan has mycophenolate mofetil 250 mg capsules in 100 count and 500 count and 500 mg tablets in 100 count and 500 count on back order and the company estimates a release date of early-November 2019. The 250 mg and 500 mg capsules in 100 count unit-dose packs are on back order and the company estimates a release date of mid-December 2019.
    • Sandoz has mycophenolate mofetil 250 mg capsules in 1,440 count are on back order and the company cannot estimate a release date.

Updated

Updated October 18, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created July 31, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins